Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
ADT, androgen deprivation therapy
ASCVD, atherosclerotic cardiovascular disease
CI, confidence interval
DSMB, Data Safety Monitoring Board
GnRH, gonadotropin-releasing hormone
MACE, major adverse cardiovascular event
cardiovascular safety
outcomes
prostate cancer
Journal
JACC. CardioOncology
ISSN: 2666-0873
Titre abrégé: JACC CardioOncol
Pays: United States
ID NLM: 101761697
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
10
09
2019
revised:
15
01
2020
accepted:
16
01
2020
entrez:
16
8
2021
pubmed:
17
3
2020
medline:
17
3
2020
Statut:
epublish
Résumé
This study will compare the incidence of major adverse cardiovascular events (MACEs) with androgen deprivation therapy (ADT) among men with advanced prostate cancer who are being treated with a gonadotropin-releasing hormone (GnRH) antagonist versus a GnRH agonist. Treatment of advanced prostate cancer with ADT might increase the risk of subsequent cardiovascular events among men with known atherosclerotic cardiovascular disease (ASCVD), but a recent meta-analysis suggested that this risk might be lower with ADT using a GnRH antagonist versus a GnRH agonist. PRONOUNCE is a multicenter, prospective, randomized, open, blinded endpoint trial that will enroll approximately 900 patients with advanced prostate cancer and pre-existing ASCVD who will be treated with ADT. Participants will be randomized to receive the GnRH antagonist degarelix or the GnRH agonist leuprolide as ADT for 12 months. The primary endpoint is time from randomization to first confirmed, adjudicated occurrence of a MACE, which is defined as a composite of all-cause death, nonfatal myocardial infarction, or nonfatal stroke through 12 months of ADT treatment. Baseline cardiovascular biomarkers (high-sensitivity C-reactive protein, high-sensitivity troponin T, and N-terminal pro-brain natriuretic peptide), as well as serial inflammatory and immune biomarkers, will be evaluated in exploratory analyses. As of October 1, 2019, a total of 364 patients have been enrolled. The mean age is 74 years, 90% are white, 80% have hypertension or dyslipidemia, 30% diabetes mellitus, 40% have had a previous myocardial infarction, and 65% have had previous revascularization. Regarding prostate cancer features at randomization, 48% of the patients had localized disease, 23% had locally advanced disease, and 18% had metastatic disease. PRONOUNCE is the first prospective cardiovascular outcomes trial in advanced prostate cancer that will delineate whether the risk of subsequent cardiovascular events associated with ADT is lower with a GnRH antagonist versus a GnRH agonist for men with pre-existing ASCVD. (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease [PRONOUNCE]; NCT02663908).
Sections du résumé
OBJECTIVES
OBJECTIVE
This study will compare the incidence of major adverse cardiovascular events (MACEs) with androgen deprivation therapy (ADT) among men with advanced prostate cancer who are being treated with a gonadotropin-releasing hormone (GnRH) antagonist versus a GnRH agonist.
BACKGROUND
BACKGROUND
Treatment of advanced prostate cancer with ADT might increase the risk of subsequent cardiovascular events among men with known atherosclerotic cardiovascular disease (ASCVD), but a recent meta-analysis suggested that this risk might be lower with ADT using a GnRH antagonist versus a GnRH agonist.
METHODS
METHODS
PRONOUNCE is a multicenter, prospective, randomized, open, blinded endpoint trial that will enroll approximately 900 patients with advanced prostate cancer and pre-existing ASCVD who will be treated with ADT. Participants will be randomized to receive the GnRH antagonist degarelix or the GnRH agonist leuprolide as ADT for 12 months. The primary endpoint is time from randomization to first confirmed, adjudicated occurrence of a MACE, which is defined as a composite of all-cause death, nonfatal myocardial infarction, or nonfatal stroke through 12 months of ADT treatment. Baseline cardiovascular biomarkers (high-sensitivity C-reactive protein, high-sensitivity troponin T, and N-terminal pro-brain natriuretic peptide), as well as serial inflammatory and immune biomarkers, will be evaluated in exploratory analyses.
RESULTS
RESULTS
As of October 1, 2019, a total of 364 patients have been enrolled. The mean age is 74 years, 90% are white, 80% have hypertension or dyslipidemia, 30% diabetes mellitus, 40% have had a previous myocardial infarction, and 65% have had previous revascularization. Regarding prostate cancer features at randomization, 48% of the patients had localized disease, 23% had locally advanced disease, and 18% had metastatic disease.
CONCLUSIONS
CONCLUSIONS
PRONOUNCE is the first prospective cardiovascular outcomes trial in advanced prostate cancer that will delineate whether the risk of subsequent cardiovascular events associated with ADT is lower with a GnRH antagonist versus a GnRH agonist for men with pre-existing ASCVD. (A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease [PRONOUNCE]; NCT02663908).
Identifiants
pubmed: 34396210
doi: 10.1016/j.jaccao.2020.01.004
pii: S2666-0873(20)30005-3
pmc: PMC8352040
doi:
Banques de données
ClinicalTrials.gov
['NCT02663908']
Types de publication
Journal Article
Langues
eng
Pagination
70-81Informations de copyright
© 2020 The Authors.
Références
J Androl. 2008 Sep-Oct;29(5):534-9
pubmed: 18567642
J Clin Oncol. 2007 Jun 10;25(17):2420-5
pubmed: 17557956
BMJ. 2008 Dec 09;337:a2467
pubmed: 19066258
J Natl Cancer Inst. 2010 Oct 20;102(20):1584-98
pubmed: 20937991
Blood Press. 1992 Aug;1(2):113-9
pubmed: 1366259
J Endocrinol. 2010 Aug;206(2):217-24
pubmed: 20484148
Circulation. 2019 Mar 26;139(13):e579-e602
pubmed: 30786722
Eur Urol. 2009 Jun;55(6):1269-77
pubmed: 19249153
J Clin Oncol. 2011 Oct 20;29(30):4014-21
pubmed: 21911717
Eur Heart J. 2013 Oct;34(38):2949-3003
pubmed: 23996286
Cancer. 2007 Oct 1;110(7):1493-500
pubmed: 17657815
Eur Urol. 2020 Feb;77(2):158-166
pubmed: 31420248
J Natl Cancer Inst. 2008 Feb 20;100(4):252-60
pubmed: 18270335
J Natl Cancer Inst. 2012 Sep 5;104(17):1335-42
pubmed: 22835388
J Clin Oncol. 2006 Sep 20;24(27):4448-56
pubmed: 16983113
Cancer. 2013 May 15;119(10):1808-15
pubmed: 23400678
Urology. 2008 Feb;71(2):318-22
pubmed: 18308111
Circulation. 2006 Feb 14;113(6):791-8
pubmed: 16461820
Cancer. 2012 Jul 1;118(13):3397-406
pubmed: 22072494
J Am Coll Cardiol. 2018 Mar 6;71(9):1021-1034
pubmed: 29495982
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24
pubmed: 17925537
J Urol. 2011 Nov;186(5):1835-42
pubmed: 21944083
Eur Urol. 2012 Jun;61(6):1119-28
pubmed: 22336376
J Am Coll Cardiol. 2014 Nov 4;64(18):1929-49
pubmed: 25077860
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
J Clin Oncol. 2006 Apr 20;24(12):1868-76
pubmed: 16622261
JAMA. 2009 Aug 26;302(8):866-73
pubmed: 19706860
Breast Cancer Res. 2011 Jun 20;13(3):R64
pubmed: 21689398
JAMA. 2005 Jul 13;294(2):238-44
pubmed: 16014598
JAMA. 2005 Sep 14;294(10):1255-9
pubmed: 16160134
PLoS One. 2010 Mar 09;5(3):e9584
pubmed: 20231893
Clin Genitourin Cancer. 2019 Oct;17(5):e871-e877
pubmed: 31378578
FEBS Lett. 2002 Oct 23;530(1-3):129-32
pubmed: 12387879
Eur Urol. 2014 Mar;65(3):565-73
pubmed: 24210090
Urology. 2003 Feb;61(2 Suppl 1):14-24
pubmed: 12667883
Endocrinology. 2010 Nov;151(11):5428-37
pubmed: 20861231
J Urol. 2019 Dec;202(6):1199-1208
pubmed: 31188734
J Natl Cancer Inst. 2004 Sep 1;96(17):1311-21
pubmed: 15339969
J Clin Oncol. 2015 Apr 10;33(11):1243-51
pubmed: 25732167
J Clin Oncol. 2007 Nov 1;25(31):4952-60
pubmed: 17971593